Financial reports
ARS
2023 FY
Annual report to shareholders
27 Mar 24
10-Q
2024 Q3
Quarterly report
18 Mar 24
10-Q
2024 Q2
Quarterly report
15 Dec 23
10-Q
2024 Q1
Quarterly report
18 Sep 23
NT 10-Q
Notice of late quarterly filing
15 Sep 23
10-K
2023 FY
Annual report
31 Jul 23
10-Q
2023 Q3
Quarterly report
16 Mar 23
10-Q
2022 Q2
Quarterly report
14 Dec 22
10-Q
2023 Q1
Quarterly report
14 Sep 22
10-K
2022 FY
Annual report
28 Jul 22
Current reports
8-K
Departure of Directors or Certain Officers
24 Nov 23
8-K
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
15 Nov 23
8-K
Changes in Registrant's Certifying Accountant
9 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
7 Sep 23
8-K
Changes in Registrant's Certifying Accountant
4 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Jul 23
8-K
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000
11 May 23
8-K
Other Events
2 Feb 23
8-K
Submission of Matters to a Vote of Security Holders
30 Dec 22
8-K
Departure of Directors or Certain Officers
18 Nov 22
Registration and prospectus
S-3/A
Shelf registration (amended)
21 Sep 23
S-3/A
Shelf registration (amended)
11 Sep 23
S-3/A
Shelf registration (amended)
4 Aug 23
SC TO-I/A
Issuer tender offer statement (amended)
15 Jun 23
S-3
Shelf registration
9 Jun 23
SC TO-I
Issuer tender offer statement
11 May 23
424B3
Prospectus supplement
19 Nov 21
S-3
Shelf registration
8 Nov 21
D
$70M in equity / securities to be acquired, sold $70M, 19 investors
1 Sep 21
424B5
Prospectus supplement for primary offering
23 Aug 21
Proxies
DEF 14A
Definitive proxy
27 Mar 24
DEF 14A
Definitive proxy
31 Jul 23
PRE 14A
Preliminary proxy
19 Jul 23
DEF 14A
Definitive proxy
5 Jun 23
PRE 14A
Preliminary proxy
25 May 23
DEF 14A
Definitive proxy
25 Nov 22
PRE 14A
Preliminary proxy
15 Nov 22
DEFA14A
Additional proxy soliciting materials
15 Aug 22
DEFA14A
Additional proxy soliciting materials
28 Jul 22
DFAN14A
Additional proxy materials by non-management
28 Jul 22
Other
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
27 Sep 23
CORRESP
Correspondence with SEC
4 Aug 23
UPLOAD
Letter from SEC
26 Jun 23
CORRESP
Correspondence with SEC
5 Jun 23
CORRESP
Correspondence with SEC
30 May 23
UPLOAD
Letter from SEC
19 May 23
EFFECT
Notice of effectiveness
18 Nov 21
CORRESP
Correspondence with SEC
15 Nov 21
UPLOAD
Letter from SEC
15 Nov 21
Ownership
SC 13G
Ayrton Capital LLC
14 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
3
FEMASYS INC
28 Nov 23
4
ROBERT WEINSTEIN
22 Nov 23
4
WAYNE REMELL WALKER
22 Nov 23
4
Carlos Trujillo
22 Nov 23
4
Joshua Silverman
22 Nov 23
4
JONATHAN SCHECHTER
22 Nov 23
4
Michael M Abecassis
22 Nov 23
SC 13D
FEMASYS INC
22 Nov 23